Market Overview

Allergan Earnings Are On Deck: Here's Why They Should Meet Expectations

Related AGN
The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease
5 Biggest Price Target Changes For Wednesday
Should You Follow Seth Klarman and David Tepper Into Allergan? (GuruFocus)
Related TEVA
Outside Of Apple, Here Are 6 Other Stocks Warren Buffett Bought In Q4
How McKesson Will Stand The Test Of Amazon
Einhorn Discusses Worst Ever Performance for Greenlight (GuruFocus)

Allergan PLC (NYSE: AGN) is scheduled to announce its second quarter financial results before the market opens on Thursday.

Ahead of the report, Evercore ISI analysts Umer Raffat and Dan Chung went through IMS data, pricing trends, transcripts, and other documents “to put everything in one place. Acknowledging limitations of IMS, analysis suggests Allergan should be able to meet consensus expectations,” the experts explain.

Their note includes a 40-page slideshow that looks into Allergan’s quarter, which is making investors somewhat nervous. Below are the main three reasons behind their worries.

1) The second quarter of 2014 establishes a hard-to-beat precedent. Legacy Allergan sales surged 16 percent year-over-year in the second quarter of last year.

2) This is the first full quarter with legacy Allergan.

3) Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) “top-lined 2Q15 earnings along with generics acquisition ... but Allergan didn’t.”

Related Link: 5 Biotechs With Catalysts Coming This Week

For the second quarter, Evercore ISI expects earnings of $4.39 per share on revenue of $5.7 billion despite FX headwinds. The analysts anticipate Legacy Allergan sales of $1.919 billion will be driven by Eye Care products ($841 million) and Botox ($621 million).

The analysts also notice that, in the first quarter call, management cited double-digit growth (on a constant currency basis) as of May 11 2015.

Key Issues For The Call

The slideshow goes on to look into some of the key issues to look for at the call:

  • M&A priorities.
  • Integration and revenue performance.
  • FCF conversion.

Latest Ratings for AGN

Feb 2018Credit SuisseMaintainsOutperformOutperform
Feb 2018Leerink SwannMaintainsOutperformOutperform
Feb 2018Bank of AmericaMaintainsBuyBuy

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Dan Chung Evercore ISI Umer RaffatAnalyst Color Previews Analyst Ratings Trading Ideas


Related Articles (TEVA + AGN)

View Comments and Join the Discussion!